JOHN KIRKWOOD to Survival Rate
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Survival Rate.
Connection Strength
0.587
-
Randomized, Placebo-Controlled, Phase III Trial of Yeast-Derived Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With No Evidence of Disease After Complete Surgical Resection of Locally Advanced and/or Stage IV Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E4697). J Clin Oncol. 2015 Dec 01; 33(34):4066-76.
Score: 0.049
-
Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014; 9(2):e87705.
Score: 0.044
-
Pediatric melanoma: analysis of an international registry. Cancer. 2013 Nov 15; 119(22):4012-9.
Score: 0.043
-
Progression of cutaneous melanoma: implications for treatment. Clin Exp Metastasis. 2012 Oct; 29(7):775-96.
Score: 0.040
-
Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009 Dec; 1182:47-57.
Score: 0.033
-
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008 Feb 01; 26(4):527-34.
Score: 0.029
-
Phase I/II randomized trial of intrahepatic arterial infusion chemotherapy with cisplatin and chemoembolization with cisplatin and polyvinyl sponge in patients with ocular melanoma metastatic to the liver. Melanoma Res. 2004 Jun; 14(3):217-22.
Score: 0.023
-
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000 Jun; 18(12):2444-58.
Score: 0.017
-
Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020 03; 21(3):358-372.
Score: 0.017
-
A Th1/IFN? Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 04 01; 26(7):1725-1735.
Score: 0.016
-
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2019 12 10; 37(35):3350-3358.
Score: 0.016
-
A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma. Cancer. 1999 May 01; 85(9):1979-84.
Score: 0.016
-
Systemic adjuvant treatment of high-risk melanoma: the role of interferon alfa-2b and other immunotherapies. Eur J Cancer. 1998 Jul; 34 Suppl 3:S12-7.
Score: 0.015
-
Adjuvant therapy of melanoma. Semin Surg Oncol. 1998 Jun; 14(4):302-10.
Score: 0.015
-
Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
Score: 0.014
-
High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med. 2017 Nov; 6(11):2576-2585.
Score: 0.014
-
The adjuvant treatment of malignant melanoma. J Fla Med Assoc. 1997 Mar; 84(3):147-52.
Score: 0.014
-
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. Cancer Immunol Immunother. 2016 12; 65(12):1533-1544.
Score: 0.013
-
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996 Jan; 14(1):7-17.
Score: 0.013
-
Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma. Cancer J Sci Am. 1995 Nov-Dec; 1(4):274-80.
Score: 0.012
-
Blood mRNA expression profiling predicts survival in patients treated with tremelimumab. Clin Cancer Res. 2014 Jun 15; 20(12):3310-8.
Score: 0.011
-
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clin Cancer Res. 2014 Jun 15; 20(12):3328-37.
Score: 0.011
-
Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
Score: 0.011
-
Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
Score: 0.011
-
Mastectomy versus breast conservation surgery: mental health effects at long-term follow-up. Health Psychol. 1992; 11(6):349-54.
Score: 0.010
-
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
Score: 0.008
-
Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery. 2007 Mar; 60(3):471-81; discussion 481-2.
Score: 0.007
-
Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer. 2005 Dec 15; 104(12):2784-91.
Score: 0.006
-
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec; 123(12):1639-43.
Score: 0.006
-
Second primary cancers after enrollment in the COMS trials for treatment of choroidal melanoma: COMS Report No. 25. Arch Ophthalmol. 2005 May; 123(5):601-4.
Score: 0.006
-
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005 Jan 01; 23(1):133-41.
Score: 0.006
-
Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004 Jun 01; 22(11):2101-7.
Score: 0.006
-
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
Score: 0.005
-
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33.
Score: 0.005
-
Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol. 2001 Dec; 8(10):766-70.
Score: 0.005
-
Burden of illness associated with metastatic melanoma: an audit of 100 consecutive referral center cases. Cancer. 2001 May 01; 91(9):1814-21.
Score: 0.005
-
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol. 2001 Feb 01; 19(3):812-23.
Score: 0.004
-
A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer. 1999 Sep; 25(3):199-206.
Score: 0.004
-
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1998 May; 16(5):1743-51.
Score: 0.004
-
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. Am J Clin Oncol. 1996 Dec; 19(6):546-51.
Score: 0.003